qls31905
mAbexperimentalBi-specific
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Oct 25, 2021 (NCT05278832)
Timeline
Indications
Mechanism of action
cd3e
- Claudin-18BINDING AGENT
CLDN18 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07151872 | Phase 2 | Sep 30, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT07079228 | Phase 3 | Sep 8, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT06942767 | Phase 2 | Jun 30, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT06446388 | Phase 2 | Jun 30, 2024 | Qilu Pharmaceutical Co., Ltd. |
| NCT06041035 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2023 | Qilu Pharmaceutical Co., Ltd. |
| NCT05278832 | Phase 1 | Oct 25, 2021 | Qilu Pharmaceutical Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 6 | 6 | 3 | 2021 |
1 organizations
Page 1 / 1